Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind placebo-controlled study of ASP2151 in herpes simplex
jRCT2080222243Phase 3Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in herpes simplex (HSV), herpes labialis and genital herpes comparing ASP2151 200 mg once daily with Placebo once daily (2 arms). Started Oct 2013; status: completed.
02
Drugs
Amenamevir
03
Conditions
herpes simplex (HSV)herpes labialisgenital herpes
Beyond the preview
Go deeper on jRCT2080222243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222243.